<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A specific immune response against the individual idiotypic determinants of clonal immunoglobulins can be elicited in patients with B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We analyze the clinical outcome and the presence of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in the blood of 8 patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, vaccinated with autologous idiotype protein from their <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells </plain></SENT>
<SENT sid="2" pm="."><plain>After a median follow-up of 90 months (range: 54 to 128), <z:hpo ids='HP_0000001'>all</z:hpo> patients, except 1, remain in complete clinical remission and 5 are in complete molecular remission </plain></SENT>
<SENT sid="3" pm="."><plain>Our results suggest that idiotype vaccination induces long-lasting clinical and molecular remissions and constitutes a potential curative treatment in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients </plain></SENT>
</text></document>